Login to Your Account


Ascendis advances hGH program with phase III kick-off

By Michael Fitzhugh
Staff Writer

Thursday, August 11, 2016

A pivotal phase III study launched by Ascendis Pharma A/S to test its long-acting Transcon growth hormone (GH) in children with GH deficiency moves the Danish company one step closer to entering the $3 billion daily human GH market. The trial will measure annualized height velocity at 52 weeks for the company’s weekly prodrug treatment and compare it to Pfizer Inc.’s daily human GH treatment, Genotropin (somatropin).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription